TP53 and cancer: The studies presented herein, carried out in cell culture and in xenografted tumor-bearing mice, showed that low-dose doxorubicin induced EMT (Figure 1), augmented CSC numbers, promoted tumor growth, and conferred drug resistance (Figures 1, 3, 5, 7, 8) for cancer cells carrying a heterozygous p53 R273H mutation.